B. Riley Securities Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $31

Benzinga Newsdesk www.benzinga.com Positive 77.9%

Neg 0% Neu 0% Pos 77.9%

B. Riley Securities analyst Madison El-Saadi maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $26 to $31.